Laboratory (LH) Earnings Date & Reports
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market... Show more
LH is expected to report earnings to rise 12.71% to $4.79 per share on July 30
Labcorp Holdings (LH) Q1 2026 Earnings Recap: Beats Estimates and Raises Full-Year Outlook
Key Takeaways
- Revenue reached $3.54 billion, up 5.8% year-over-year (YoY), surpassing consensus estimates of $3.51 billion.
- Adjusted earnings per share (EPS, a non-GAAP measure excluding certain one-time items) of $4.25, up 10.6% YoY, beating expectations of $4.10.
- GAAP diluted EPS rose to $3.35 from $2.52 YoY, with net income of $277.8 million.
- Raised full-year 2026 revenue guidance to 5.0%-6.1% growth and adjusted EPS midpoint to $18.03, up $0.13.
- Diagnostics segment revenue up 5.0% to $2.76 billion; Biopharma Laboratory Services up 8.2% to $780.6 million.
- Free cash flow turned positive at $70.5 million, supporting $202.2 million in acquisitions and share repurchases.
Earnings Context and Why It Matters
As a leading provider of diagnostic testing and biopharma laboratory services, Labcorp Holdings Inc. (NYSE: LH) plays a critical role in healthcare delivery and drug development. This Q1 2026 report is pivotal amid ongoing recovery in routine testing volumes post-COVID, rising demand for advanced diagnostics like companion diagnostics, and biopharma sector growth. Investors watch closely for signs of sustained organic revenue growth, margin expansion from operational efficiencies including AI and robotics, and stability in health system partnerships. Strong results could affirm Labcorp's competitive edge against peers like Quest Diagnostics, influencing sector valuations and stock performance in a high-interest-rate environment.
Labcorp Holdings reported Q1 2026 revenue of $3.54 billion, a 5.8% increase from $3.35 billion in Q1 2025, driven by 3.1% organic growth, 1.4% from acquisitions net of divestitures, and 1.3% foreign exchange tailwinds. This topped consensus estimates of $3.51 billion.
Adjusted EPS came in at $4.25, up 10.6% YoY from $3.84 and exceeding forecasts of $4.10. GAAP diluted EPS was $3.35, up 32.8% from $2.52, with net income attributable to Labcorp at $277.8 million versus $212.8 million prior year.
By segment, Diagnostics Laboratories revenue grew 5.0% to $2.76 billion, with requisition volume up 2.5% and adjusted operating margin expanding 30 basis points to 16.6%. Biopharma Laboratory Services revenue rose 8.2% to $780.6 million, led by 11.3% Central Labs growth, with backlog at $8.64 billion (up 5.6% YoY) and book-to-bill of 1.04. Enterprise adjusted operating income hit $507.9 million (14.4% margin, +30 bps YoY).
The company raised FY2026 guidance: enterprise revenue $14.65-$14.80 billion (5.0%-6.1% growth), Diagnostics $11.43-$11.52 billion, Biopharma $3.22-$3.27 billion, and adjusted EPS $17.70-$18.35 (midpoint up $0.13). Free cash flow outlook unchanged at $1.24-$1.36 billion.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research process.
Market Reaction and Investor Sentiment
Labcorp shares reacted positively to the Q1 results, rising 0.82% to $259.50 in premarket trading on April 30 following the April 30 pre-market release, after closing at $257.38 the prior day. The beat on top and bottom lines, coupled with raised guidance, boosted sentiment, with commentary noting the stock "soars" on strong execution and growth momentum. Investors appeared encouraged by volume recovery, margin gains, and biopharma backlog strength, offsetting any concerns over acquisition spend.
Forward Outlook and Key Factors to Monitor
Labcorp's raised FY2026 guidance signals confidence in sustained growth, with enterprise revenue expected at 5.0%-6.1% and adjusted EPS midpoint of $18.03. Diagnostics should benefit from health system expansions, like the nationwide collaboration with Children's Hospital of Philadelphia, and consumer health growth via OnDemand tests.
In Biopharma, watch the $8.64 billion backlog and 1.04 book-to-bill ratio for pipeline visibility, alongside Central Labs momentum. Operational efficiencies from AI, robotics, and partnerships (e.g., Optum.ai, PathAI) could further lift margins.
Key risks include reimbursement pressures, volume fluctuations, and integration of acquisitions like Laboratory Alliance assets. Free cash flow generation remains vital for capital returns, with recent repurchases and a $0.72 quarterly dividend. Upcoming catalysts: MyLabcorp AI app launch in May 2026 and genomic testing expansions with Illumina.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Advertisement
General Information
a provider of medical testing services
Industry MedicalSpecialties